Sanofi makes a pre-JP Morgan splash with Kymab
The Kymab takeover represents another bold move as the French company bids to rebuild its pipeline.
Glaxo adds flesh to its oncology ambitions
As Glaxosmithkline manoeuvres to become a major player in cancer, it backs Icos among other novel mechanisms.
